Literature DB >> 18435773

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.

M Horowitz, T Vilsbøll, M Zdravkovic, M Hammer, S Madsbad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18435773     DOI： 10.1111/j.1463-1326.2008.00861.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  10 in total

Review 1.  Glucagon-like peptide analogues for type 2 diabetes mellitus.

Authors:  Deepson S Shyangdan; Pamela Royle; Christine Clar; Pawana Sharma; Norman Waugh; Alisa Snaith
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

2.  Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

Authors:  Richard E Pratley; Matthew Gilbert
Journal:  Rev Diabet Stud       Date:  2008-08-10

3.  Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.

Authors:  Leigh Macconell; Carl Brown; Kate Gurney; Jenny Han
Journal:  Diabetes Metab Syndr Obes       Date:  2012-02-20       Impact factor: 3.168

4.  Incretin-based therapies: focus on effects beyond glycemic control alone.

Authors:  Jaime A Davidson
Journal:  Diabetes Ther       Date:  2013-09-21       Impact factor: 2.945

5.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors:  D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal:  Diabetologia       Date:  2009-08-14       Impact factor: 10.122

6.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 7.  Incretin-based therapies: viewpoints on the way to consensus.

Authors:  Michael A Nauck; Tina Vilsbøll; Baptist Gallwitz; Alan Garber; Sten Madsbad
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 8.  Potential of liraglutide in the treatment of patients with type 2 diabetes.

Authors:  Carolyn F Deacon
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

9.  Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.

Authors:  Leigh MacConell; Kate Gurney; Jaret Malloy; Ming Zhou; Orville Kolterman
Journal:  Diabetes Metab Syndr Obes       Date:  2015-05-18       Impact factor: 3.168

10.  Contributions of upper gut hormones and motility to the energy intake-suppressant effects of intraduodenal nutrients in healthy, lean men - a pooled-data analysis.

Authors:  Gudrun Schober; Kylie Lange; Robert E Steinert; Amy T Hutchison; Natalie D Luscombe-Marsh; Maria F Landrock; Michael Horowitz; Radhika V Seimon; Christine Feinle-Bisset
Journal:  Physiol Rep       Date:  2016-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.